Other PSMA NEWS: Cornell University Scientists Present Results on Bzl Biologics Prostate Cancer Antibodies at America
NEW YORK, May 1, 2000 /PRNewswire via COMTEX/ -- BZL Biologics Inc. today announced that scientists from Cornell University Medical Center reported at the annual American Urological Association Meeting that a new monoclonal antibody to prostate specific membrane antigen (PSMA) produced very substantial anti-cancer activity in animal models of human prostate cancer, and, in a parallel clinical trial in patients with hormone-refractory prostate cancer, the antibody (called"J591") was able to effectively target disseminated tumor sites throughout the body while avoiding targeting of normal tissues. BZL holds the exclusive worldwide license to this technology from Cornell University.
According to Dr. Neil Bander, the Bernard and Josephine Chaus Professor and Director of the Laboratory of Urological Oncology at Cornell University Medical Center, "PSMA is the single most well-established, prostate restricted, cell surface molecule known. PSMA is present on virtually every prostate cancer and the relative amount of PSMA increases as prostate cancers become more virulent. Hormone refractory cancers express the highest levels of PSMA. For these reasons, PSMA is widely considered an ideal target for molecularly focused therapeutic strategies."
…"Several laboratories have now published studies indicating that PSMA is also expressed on the vasculature of virtually all malignancies despite its absence from normal blood vessels. This finding may allow much broader application of the PSMA antibody approach, beyond prostate cancer, to include other malignancies as well," stated Dr Bander….
Message 14013873
Jim |
